Company intelligence / Profile preview

Polichem

Lugano, Ticino, Switzerlandpolichem.com ↗

Ownership: Private
Employees: ~85
Development stage: Commercial

Overview

Polichem has a long tradition in developing innovative pharmaceutical products with a strong focus on dermatology—especially nail diseases—and gynecology. The company has more than eight marketed products globally and holds over forty patents. It was acquired by Almirall S.A. in November 2015. Its lead areas are dermatological conditions such as onychomycosis and nail psoriasis; it also markets gynecological treatments like Nifuratel/Nystatin for vulvovaginal candidiasis.

Therapeutic areas: NeurologyPulmonologyDermatologyInfectious Diseases
Modalities: Small moleculesMedical devicesDermocosmetics
Industry: Biotech

Drug pipeline

9 assets

Gynomunal

8 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Polichem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polichem.

Explore the full profile